Update on CALLA Phase III trial for Imfinzi
24 March 2022 07:00 GMT Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer The CALLA Phase III trial for AstraZeneca’s Imfinzi (durvalumab) given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone in the treatment of patients with locally advanced cervical cancer. Bradley Monk, MD, FACOG, FACS, Professor at the University of Arizona College of Medicine and principal investigator